© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 1, 46-52,
January 1, 2003
© 2003 Oxford University Press
ARTICLE |
Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis
Affiliations of authors: M. E. Sherman, S. Wacholder, P. E. Castle, M. Schiffman, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; A. T. Lorincz, I. Mielzynska-Lohnas, Digene Corporation, Gaithersburg, MD; D. R. Scott, A. G. Glass, B. B. Rush, Kaiser Permanente Northwest Division, Portland, OR.
Correspondence to: Mark E. Sherman, M.D., National Cancer Institute, Division of Cancer Epidemiology and Genetics, 6120 Executive Blvd., Rm. 7080, Rockville, MD 20892-7374 (e-mail: shermanm{at}mail.nih.gov).
Background: Annual Pap smear screening has been favored over less frequent screening in the United States to minimize the risk of cervical cancer. We evaluated whether simultaneous screening with a Pap test and human papillomavirus (HPV) testing is useful for assessing the risk for cervical intraepithelial neoplasia (CIN) 3 or cervical cancer. Methods: We enrolled 23 702 subjects in a study of HPV infection at Kaiser Permanente, Northwest Division, Portland, OR. Data were analyzed for 20 810 volunteers who were at least 16 years old (mean = 35.9 years) with satisfactory baseline Pap tests and suitable samples for HPV testing. Women were followed for up to 122 months (from April 1, 1989, to June 30, 1999) to determine the risk for histopathologically confirmed CIN3 or cancer. Results: Among 171 women with CIN3 or cancer diagnosed over 122 months, 123 (71.9%, 95% confidence interval [CI] = 65.2% to 78.7%) had baseline Pap results of atypical squamous cells or worse and/or a positive HPV test, including 102 (86.4%, 95% CI = 80.3% to 92.6%) of the 118 cases diagnosed within the first 45 months of follow-up. During this 45-month period, the cumulative incidence of CIN3 or cancer was 4.54% (95% CI = 3.61% to 5.46%) among women with a Pap test result of atypical squamous cells or worse, positive HPV tests, or both compared with 0.16% (95% CI = 0.08% to 0.24%) among women with negative Pap and HPV tests. Age, screening behavior, a history of cervical cancer precursors, and a history of treatment for CIN minimally affected results. Conclusions: Negative baseline Pap and HPV tests were associated with a low risk for CIN3 or cancer in the subsequent 45 months, largely because a negative HPV test was associated with a decreased risk of cervical neoplasia. Negative combined test results should provide added reassurance for lengthening the screening interval among low-risk women, whereas positive results identify a relatively small subgroup that requires more frequent surveillance.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Leinonen, P. Nieminen, L. Kotaniemi-Talonen, N. Malila, J. Tarkkanen, P. Laurila, and A. Anttila Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting J Natl Cancer Inst, November 9, 2009; (2009) djp367v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Casamitjana, M. Sala, D. Ochoa, P. Fuste, X. Castells, F. Alameda, and SRHCP group Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population Eur J Public Health, October 1, 2009; 19(5): 499 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Shi, J. L. Belinson, F.-H. Zhao, R. G. Pretorius, J. Li, J.-F. Ma, F. Chen, W. Xiang, Q.-J. Pan, X. Zhang, et al. Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China Am. J. Epidemiol., September 15, 2009; 170(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Cox, A. T. Moriarty, and P. E. Castle Commentary on Statement on HPV DNA Test Utilization Am J Clin Pathol, June 1, 2009; 131(6): 770 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Naucler, W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, O. Forslund, B.-G. Hansson, et al. Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening J Natl Cancer Inst, January 21, 2009; 101(2): 88 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dillner, M. Rebolj, P. Birembaut, K.-U. Petry, A. Szarewski, C. Munk, S. de Sanjose, P. Naucler, B. Lloveras, S. Kjaer, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study BMJ, October 13, 2008; 337(oct13_1): a1754 - a1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening? Am. J. Epidemiol., July 15, 2008; 168(2): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S F Derchain, L O Sarian, P Naud, C Roteli-Martins, A Longatto-Filho, S Tatti, M Branca, M Erzen, L Serpa-Hammes, J Matos, et al. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study J Med Screen, June 1, 2008; 15(2): 97 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Monsonego, G. Pollini, M. J. Evrard, P. Sednaoui, L. Monfort, D. Quinzat, R. Dachez, and K. Syrjanen Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear Int J STD AIDS, June 1, 2008; 19(6): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gravitt, M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Kiviat, S. E. Hawes, and Q. Feng Screening for Cervical Cancer in the Era of the HPV Vaccine--The Urgent Need for Both New Screening Guidelines and New Biomarkers J Natl Cancer Inst, March 5, 2008; 100(5): 290 - 291. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Naucler, W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, B. Johansson, O. Forslund, et al. Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer N. Engl. J. Med., October 18, 2007; 357(16): 1589 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Gravitt, L. J. van Doorn, W. Quint, M. Schiffman, A. Hildesheim, A. G. Glass, B. B. Rush, J. Hellman, M. E. Sherman, R. D. Burk, et al. Human Papillomavirus (HPV) Genotyping Using Paired Exfoliated Cervicovaginal Cells and Paraffin-Embedded Tissues To Highlight Difficulties in Attributing HPV Types to Specific Lesions J. Clin. Microbiol., October 1, 2007; 45(10): 3245 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Insinga, A. G. Glass, E. R. Myers, and B. B. Rush Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss Med Decis Making, August 1, 2007; 27(4): 414 - 422. [Abstract] [PDF]
|
|
|
|
 |
|
 P. E. Castle, J. Dockter, C. Giachetti, F. A.R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer Clin. Cancer Res., May 1, 2007; 13(9): 2599 - 2605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Solomon, N. Breen, and T. McNeel Cervical Cancer Screening Rates in the United States and the Potential Impact of Implementation of Screening Guidelines CA Cancer J Clin, March 1, 2007; 57(2): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, M. Sadorra, F. Garcia, E. B. Holladay, and J. Kornegay Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology J. Clin. Microbiol., November 1, 2006; 44(11): 3915 - 3917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Hesselink, N. W. J. Bulkmans, J. Berkhof, A. T. Lorincz, C. J. L. M. Meijer, and P. J. F. Snijders Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening Program. J. Clin. Microbiol., October 1, 2006; 44(10): 3680 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berkhof, N. W.J. Bulkmans, M. C.G. Bleeker, S. Bulk, P. J.F. Snijders, F. J. Voorhorst, and C. J.L.M. Meijer Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1268 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Khan, P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice J Natl Cancer Inst, July 20, 2005; 97(14): 1072 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soderlund-Strand, P. Rymark, P. Andersson, J. Dillner, and L. Dillner Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia J. Clin. Microbiol., July 1, 2005; 43(7): 3260 - 3266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, M. Schiffman, D. R. Scott, M. E. Sherman, A. G. Glass, B. B. Rush, J. E. Schussler, S. Wacholder, and A. T. Lorincz Semiquantitative Human Papillomavirus Type 16 Viral Load and the Prospective Risk of Cervical Precancer and Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1311 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Harris, R. D. Burk, J. M. Palefsky, L. S. Massad, J. Y. Bang, K. Anastos, H. Minkoff, C. B. Hall, M. C. Bacon, A. M. Levine, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test Results JAMA, March 23, 2005; 293(12): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Molden, I. Kraus, F. Karlsen, H. Skomedal, J. F. Nygard, and B. Hagmar Comparison of Human Papillomavirus Messenger RNA and DNA Detection: A Cross-sectional Study of 4,136 Women >30 Years of Age with a 2-Year Follow-up of High-Grade Squamous Intraepithelial Lesion Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 367 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Insinga, A. G. Glass, and B. B. Rush Pap Screening in a U.S. Health Plan Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 355 - 360. [Abstract] [Full Text]
|
|
|
|
|
|
N. F. Schlecht, R. W. Platt, A. Negassa, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions Am. J. Epidemiol., November 1, 2003; 158(9): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, A. T. Lorincz, D. R. Scott, M. E. Sherman, A. G. Glass, B. B. Rush, S. Wacholder, R. D. Burk, M. M. Manos, J. E. Schussler, et al. Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer J. Clin. Microbiol., September 1, 2003; 41(9): 4022 - 4030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schiffman and S. K. Kjaer Chapter 2: Natural History of Anogenital Human Papillomavirus Infection and Neoplasia J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sherman Chapter 11: Future Directions in Cervical Pathology J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Franco Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Solomon Chapter 14: Role of Triage Testing in Cervical Cancer Screening J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 97 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Crum, D. W. Abbott, and B. J. Quade Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era J. Clin. Oncol., May 15, 2003; 21(90100): 224s - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Wright Jr. and M. Schiffman Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening N. Engl. J. Med., February 6, 2003; 348(6): 489 - 490. [Full Text] [PDF]
|
|